TY  - GEN
AU  - Kawazoe,Akihito
AU  - Yamaguchi,Kensei
AU  - Yasui,Hisateru
AU  - Negoro,Yuji
AU  - Azuma,Mizutomo
AU  - Amagai,Kenji
AU  - Hara,Hiroki
AU  - Baba,Hideo
AU  - Tsuda,Masahiro
AU  - Hosaka,Hisashi
AU  - Kawakami,Hisato
AU  - Oshima,Takashi
AU  - Omuro,Yasushi
AU  - Machida,Nozomu
AU  - Esaki,Taito
AU  - Yoshida,Kazuhiro
AU  - Nishina,Tomohiro
AU  - Komatsu,Yoshito
AU  - Han,Shi R
AU  - Shiratori,Shinichi
AU  - Shitara,Kohei
TI  - Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study
SN  - 1879-0852
PY  - 2020///1023
KW  - Adult
KW  - Aged
KW  - Antibodies, Monoclonal, Humanized
KW  - administration & dosage
KW  - Antineoplastic Agents, Immunological
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - B7-H1 Antigen
KW  - analysis
KW  - Drug Combinations
KW  - Esophageal Neoplasms
KW  - drug therapy
KW  - Esophagogastric Junction
KW  - immunology
KW  - Female
KW  - Follow-Up Studies
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Oxaliplatin
KW  - Oxonic Acid
KW  - Progression-Free Survival
KW  - Receptor, ErbB-2
KW  - Remission Induction
KW  - methods
KW  - Stomach Neoplasms
KW  - Tegafur
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/j.ejca.2020.02.002
ER  -